Search by Drug Name or NDC
NDC 00002-7575-01 Omvoh 20 mg/mL Details
Omvoh 20 mg/mL
Omvoh is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is MIRIKIZUMAB.
MedlinePlus Drug Summary
Mirikizumab-mrkz injection is used to treat ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) in adults. Mirikizumab-mrkz injection is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of ulcerative colitis.
Related Packages: 00002-7575-01Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Mirikizumab-mrkz Injection
Product Information
NDC | 00002-7575 |
---|---|
Product ID | 0002-7575_83c555b7-3807-4f0b-8812-63b6082d026c |
Associated GPIs | |
GCN Sequence Number | 085440 |
GCN Sequence Number Description | mirikizumab-mrkz VIAL 300MG/15ML INTRAVEN |
HIC3 | V4E |
HIC3 Description | IL-23 RECEPTOR ANTAGONIST, MONOCLONAL ANTIBODY |
GCN | 54923 |
HICL Sequence Number | 049282 |
HICL Sequence Number Description | MIRIKIZUMAB-MRKZ |
Brand/Generic | Brand |
Proprietary Name | Omvoh |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | mirikizumab-mrkz |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, SOLUTION |
Route | INTRAVENOUS |
Active Ingredient Strength | 20 |
Active Ingredient Units | mg/mL |
Substance Name | MIRIKIZUMAB |
Labeler Name | Eli Lilly and Company |
Pharmaceutical Class | Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA] |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA761279 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00002-7575-01 (00002757501)
NDC Package Code | 0002-7575-01 |
---|---|
Billing NDC | 00002757501 |
Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-7575-01) / 15 mL in 1 VIAL, SINGLE-DOSE |
Marketing Start Date | 2023-10-26 |
NDC Exclude Flag | N |
Pricing Information | N/A |